Research trials
The trials moving the whole field forward.
A living database of the clinical trials behind every therapy on this site — across cell replacement, encapsulation, gene editing, immune therapy, antigen therapy, screening and devices. Every row shows the phase, recruitment status, where it runs, and which therapy it advances. Expand for the summary, primary endpoint, and the ClinicalTrials.gov record.
Adjunct metabolic trial adding pioglitazone or placebo after a dapagliflozin lead-in in type 1 diabetes, testing whether the combination improves HbA1c without
Phase
Status
Active
Where
US · OTHER
McGill phase 4 randomized trial testing low-dose empagliflozin added to automated insulin delivery for adults with T1D who are not meeting time-in-range targets
Phase
Status
Recruiting
Where
CA
Steno Copenhagen study testing whether pre-exercise low-dose glucagon prevents or blunts exercise-related glucose drops in adults with T1D using automated insul
Phase
Status
Recruiting
Where
EU
Advances
ZT-01 glucagon-response restorer
Phase 4/pediatric stage-2 teplizumab study, relevant after the expanding Tzield label and screening-to-treatment pathway.
Phase
Status
Active
Where
US
Advances
Teplizumab (Tzield)
Tel Aviv pilot trial comparing mealtime versus post-meal dosing of ultra-rapid lispro in adults using the MiniMed 780G hybrid closed-loop system.
Phase
Status
Not yet recruiting
Where
OTHER
Advances
Ultra-rapid lispro (Lyumjev)
Phase-3 trial testing whether oral baricitinib can delay progression to clinical stage-3 T1D in at-risk stage-1b/2 children and adults.
Phase
Status
Recruiting
Where
US · EU · OTHER
Advances
Baricitinib (JAK1/2 inhibitor)
Phase-3 trial testing baricitinib in children and adults newly diagnosed with stage-3 T1D, following the positive BANDIT phase-2 result.
Phase
Status
Recruiting
Where
US · EU · OTHER
Advances
Baricitinib (JAK1/2 inhibitor)
Sanofi's large Phase 3 confirmatory trial for teplizumab in newly diagnosed stage-3 type 1 diabetes. It is recruiting 723 participants aged 1-25 within 56 days
Phase
Status
Recruiting
Where
US · CA · AU · UK · EU · JP · OTHER
Advances
Teplizumab for new-onset T1D (Tzield)
vTv Therapeutics phase 3 trial testing cadisegliatin, a liver-selective glucokinase activator, as an insulin adjunct to reduce level-2/3 hypoglycemia in adults
Phase
Status
Active
Where
US
Advances
Cadisegliatin (oral glucokinase activator)
UC San Diego randomized crossover study asking whether a dual continuous glucose-ketone monitor can reduce ketone exposure while adults with type 1 diabetes tak
Phase
Status
Not yet recruiting
Where
US
Advances
Concept: closed loops that act on ketones
Nanjing Medical University randomized phase 3 study testing whether dimethyl fumarate capsules preserve C-peptide in adults with newly diagnosed type 1 diabetes
Phase
Status
Recruiting
Where
OTHER
Advances
Dimethyl fumarate for beta-cell preservation
Lilly phase 3 long-term safety and efficacy trial of weekly tirzepatide versus placebo in adults with T1D and overweight or obesity.
Phase
Status
Active
Where
US · CA · EU · OTHER
Advances
Tirzepatide as an adjunct in T1D
Novo Nordisk phase 3 trial comparing once-weekly insulin icodec with once-daily glargine U100, both with insulin aspart, in adults with type 1 diabetes.
Phase
Status
Recruiting
Where
US · AU · CA · EU
Advances
Once-weekly insulin icodec (Awiqli)
A phase-3 trial asking a question almost nobody else asks: can an immune therapy still protect insulin-producing cells in people who are one to two years past d
Phase
Status
Not yet recruiting
Where
US
Advances
SAB-142 (fully human anti-thymocyte globulin)
Danish investigator-initiated phase 3 trial testing semaglutide 2.4 mg for weight, insulin-dose needs, glycemic outcomes, hypoglycemia and DKA safety in adults
Phase
Status
Not yet recruiting
Where
EU
Advances
GLP-1 drugs to rescue beta cells at diagnosis
McGill phase 3 crossover study testing semaglutide and empagliflozin, individually and combined, as adjuncts to automated insulin delivery in adults with T1D.
Phase
Status
Recruiting
Where
CA
Advances
GLP-1 drugs to rescue beta cells at diagnosis
Recruiting US/Canada Phase 3 of three years of sotagliflozin 200 mg daily versus placebo in adults with longstanding T1D and moderate-to-severe diabetic kidney
Phase
Status
Recruiting
Where
US · CA
Advances
SGLT2 / SGLT1-2 inhibitors (dapagliflozin, sotagliflozin)
Swiss randomized phase 3 study testing tirzepatide as an add-on to usual care in adults with type 1 diabetes using automated insulin delivery.
Phase
Status
Recruiting
Where
OTHER
Advances
Tirzepatide as an adjunct in T1D
Large Lilly phase 3 study testing weekly tirzepatide versus placebo in adults with type 1 diabetes and overweight or obesity, with HbA1c as the primary endpoint
Phase
Status
Active
Where
US · EU · JP · OTHER
Advances
Tirzepatide as an adjunct in T1D
A second, separate Vertex phase 3 of the stem-cell-derived islet therapy zimislecel, in people with type 1 diabetes who already have a kidney transplant. Becaus
Phase
Status
Recruiting
Where
US · CA · OTHER
Advances
Stem-cell-derived islets (zimislecel / VX-880)
Vertex's pluripotent-stem-cell-derived islet cell therapy infused into the liver, with lifelong immunosuppression. In the published Phase 1/2 results, 10 of 12
Phase
Status
Recruiting
Where
US · CA · UK · EU · OTHER
Advances
Stem-cell-derived islets (zimislecel / VX-880)
A European randomized trial showing that switching adults with poorly controlled type 1 diabetes from insulin injections plus flash glucose monitoring to the Mi
Phase
Status
Completed
Where
UK · EU
Advances
Medtronic MiniMed 780G (SmartGuard)
Landmark UK randomized trial showing a hybrid closed-loop system (CamAPS FX) significantly improved blood-sugar time-in-range during pregnancy versus standard i
Phase
Status
Completed
Where
UK
Advances
CamAPS FX
A randomized crossover trial in 74 children aged 1-7 with type 1 diabetes found that the CamAPS FX hybrid closed-loop system (an "artificial pancreas") increase
Phase
Status
Completed
Where
UK · EU
Advances
CamAPS FX
A 16-week, 4-site U.S. randomized trial (n=101) in children aged 6–13 testing the t:slim X2 with Control-IQ automated insulin delivery against a sensor-augmente
Phase
Status
Completed
Where
US
Advances
Tandem Control-IQ
The landmark 6-month randomized trial behind Tandem's Control-IQ. People with type 1 diabetes using the t:slim X2 closed-loop system spent about 11 percentage p
Phase
Status
Completed
Where
US
Advances
Tandem Control-IQ
Phase-3 trial of Diamyd (GAD-alum) in adolescents and adults with recently diagnosed T1D who carry the HLA DR3-DQ2 haplotype, the group where prior antigen-spec
Phase
Status
Terminated
Where
US · EU · OTHER
Advances
GAD-alum antigen-specific immunotherapy (Diamyd)
A landmark NIH prevention trial that screened over 100,000 relatives of people with type 1 diabetes to test whether giving insulin (by injection or by mouth) be
Phase
Status
Completed
Where
US · CA
Advances
Oral insulin (antigen-specific immunotherapy)
Completed randomized phase-3 trial of finerenone versus placebo on top of standard care in adults with T1D and albuminuric chronic kidney disease. It met its si
Phase
Status
Completed
Where
US · UK · EU · CA · OTHER
Advances
Finerenone (Kerendia) for T1D kidney disease
Landmark pivotal randomized trial of the Beta Bionics iLet — an automated insulin-delivery system that needs no carb counting (meal announcements only) and is i
Phase
Status
Completed
Where
US
Advances
Beta Bionics iLet Bionic Pancreas
CIT-07 was the pivotal Phase 3 trial that proved transplanted donor islet cells can restore blood-sugar control and stop dangerous low-blood-sugar episodes in a
Phase
Status
Completed
Where
US · CA
Advances
Donor islet transplant (Lantidra / donislecel)
Amsterdam UMC randomized crossover trial of the Inreda bihormonal artificial pancreas in adults who have had their whole pancreas removed — people who make neit
Phase
Status
Completed
Where
EU
Advances
Inreda AP (dual-hormone)
A Phase 3 trial testing whether two short courses of the immune therapy teplizumab can preserve the body's own insulin production in 8-17-year-olds newly diagno
Phase
Status
Completed
Where
US · CA · EU · UK
Advances
Teplizumab (Tzield)
Northwestern phase 3 donor-islet transplant study for non-uremic people with difficult T1D control. Now completed, with results posted in June 2026 — but of 10
Phase
Status
Completed
Where
US
Advances
Donor islet transplant (Lantidra / donislecel)
A large international Phase 3 trial (TrialNet) testing whether a daily oral insulin capsule could delay or prevent type 1 diabetes in autoantibody-positive rela
Phase
Status
Completed
Where
US · UK · EU · CA · AU
Advances
Oral insulin (antigen-specific immunotherapy)
The first substudy of a new NIDDK adaptive platform trial that tries to slow type 1 diabetes before blood sugar ever goes abnormal. Participants have islet auto
Phase
Status
Not yet recruiting
Where
US
Advances
Golimumab (anti-TNF)
Ain Shams University phase 2/3 study testing autologous adipose-derived mesenchymal stem cells differentiated toward insulin-producing cells in adolescents with
Phase
Status
Recruiting
Where
OTHER
vTv Therapeutics phase 2a randomized crossover study testing cadisegliatin (TTP399) versus placebo as an adjunct to insulin in adults with type 1 diabetes using
Phase
Status
Not yet recruiting
Where
US
Advances
Cadisegliatin (oral glucokinase activator)
University of Virginia phase 2 trial testing Cirius Therapeutics CIR-0602K to improve time in range and lower insulin dose in adults with T1D using closed-loop
Phase
Status
Recruiting
Where
US
HealthPartners phase 2 trial developing DKA risk mitigation for people with T1D and mild-to-moderate CKD starting SGLT1/2 inhibitor therapy, using continuous gl
Phase
Status
Not yet recruiting
Where
US
Phase 2 feasibility/safety study of Diamyd antigen-specific immunotherapy in individuals at risk for type 1 diabetes.
Phase
Status
Active
Where
EU
Advances
GAD-alum antigen-specific immunotherapy (Diamyd)
Sanofi phase-2b trial of frexalimab, a CD40L antagonist, to preserve the body's own insulin production in children, adolescents and adults with newly diagnosed
Phase
Status
Active
Where
US · CA · UK · EU
Advances
Frexalimab (CD40L antagonist)
Stage-1 T1D trial testing a GLP-1 receptor agonist as an early intervention before clinical diabetes.
Phase
Status
Not yet recruiting
Where
US
Advances
GLP-1 drugs to rescue beta cells at diagnosis
Swedish randomized phase 2 trial testing ixekizumab, an anti-IL-17A antibody used in psoriasis, for preservation of residual insulin secretion in adults with ne
Phase
Status
Active
Where
EU
MannKind phase 2 single-arm study of Afrezza (Technosphere insulin) plus basal insulin in children and adolescents aged 6 to under 18 with newly diagnosed stage
Phase
Status
Recruiting
Where
US
Advances
Inhaled insulin (Afrezza)
City of Hope phase 2 donor-islet transplant protocol using a T-cell-depleting immunosuppression induction regimen and gastrin 17.
Phase
Status
Active
Where
US
Advances
Donor islet transplant (Lantidra / donislecel)
TrialNet/NIDDK phase-2 trial comparing two selective oral JAK-pathway drugs - abrocitinib and ritlecitinib - with placebo for preservation of C-peptide in newly
Phase
Status
Active
Where
US
Advances
Selective JAK inhibitors (abrocitinib / ritlecitinib)
AdventHealth study of a continuous-ketone-monitoring education plan for people with type 1 diabetes using sotagliflozin, including insulin-withdrawal testing to
Phase
Status
Not yet recruiting
Where
US
Advances
Concept: closed loops that act on ketones
Adaptive phase 2 study of MTX228 in type 1 diabetes; included as a watch-list adjunct/drug-development record.
Phase
Status
Recruiting
Where
CA
Recruiting Chinese phase 2/3 study comparing dimethyl fumarate plus standard insulin with standard insulin alone in 96 adults with residual beta-cell function.
Phase
Status
Recruiting
Where
OTHER
Advances
Dimethyl fumarate for beta-cell preservation
Recruiting US Phase 2 of subcutaneous OPT101 three times weekly. Part A is open-label dose-finding; Parts B and C are 48-week placebo-controlled C-peptide cohor
Phase
Status
Recruiting
Where
US
Advances
OPT101 (CD40-pathway peptide)
A University of Florida phase 2 trial testing low-dose ATG against placebo in newly diagnosed T1D, stratifying participants by an ex vivo immune-responder signa
Phase
Status
Recruiting
Where
US
Advances
Low-dose anti-thymocyte globulin (ATG)
Not-yet-recruiting US Phase 2 platform matching adults with long-standing T1D and early kidney or heart-risk markers to finerenone or sotagliflozin. It is a T1D
Phase
Status
Not yet recruiting
Where
US
Advances
Finerenone (Kerendia) for T1D kidney disease
Adult phase 2 trial testing repeat Bacillus Calmette-Guerin vaccination as immune/metabolic therapy for established childhood-onset T1D.
Phase
Status
Active
Where
US
Advances
Repeat BCG vaccination
Pediatric phase 2 trial testing repeat BCG vaccination in children and adolescents with established T1D. Enrolment has closed at 150 participants and the trial
Phase
Status
Active
Where
US
Advances
Repeat BCG vaccination
A TrialNet phase-2 trial of rezpegaldesleukin, a PEGylated form of interleukin-2 engineered to preferentially wake up the immune system's regulatory T cells rat
Phase
Status
Recruiting
Where
US · CA
Advances
Low-dose interleukin-2 (IL-2)
A TrialNet Phase 2 trial testing whether a short course of the B-cell-depleting antibody rituximab-pvvr, followed by the co-stimulation blocker abatacept, prese
Phase
Status
Active
Where
US · AU
Advances
Abatacept (CTLA4-Ig)
Study evaluating ketone thresholds intended to minimize ketosis risk for people with T1D using dapagliflozin.
Phase
Status
Not yet recruiting
Where
AU
The first properly powered test of SAB-142, an anti-thymocyte globulin made from human antibodies rather than rabbit ones. Low-dose rabbit ATG already preserves
Phase
Status
Recruiting
Where
US · UK · EU · AU
Advances
SAB-142 (fully human anti-thymocyte globulin)
McGill 2x4 factorial trial testing weekly semaglutide plus simplified meal strategies in people with T1D using closed-loop insulin therapy.
Phase
Status
Recruiting
Where
CA
Advances
GLP-1 drugs to rescue beta cells at diagnosis
Saudi phase 2 randomized trial testing Shingrix, semaglutide, their combination, or placebo in adults with recent-onset type 1 diabetes to assess whether immune
Phase
Status
Not yet recruiting
Where
OTHER
Advances
GLP-1 drugs to rescue beta cells at diagnosis
Recruiting UK Phase 2 of 16 weeks of sotagliflozin 200 mg daily versus placebo in adults with Type 1 diabetes and heart failure or high risk of heart failure. T
Phase
Status
Recruiting
Where
UK
Advances
SGLT2 / SGLT1-2 inhibitors (dapagliflozin, sotagliflozin)
Small phase 2 placebo-controlled study testing whether sorafenib can preserve mixed-meal-stimulated C-peptide in adults with new-onset type 1 diabetes.
Phase
Status
Not yet recruiting
Where
OTHER
Randomized phase 2 study testing difluoromethylornithine (DFMO), a polyamine-pathway drug, to reduce beta-cell stress and preserve remaining insulin production
Phase
Status
Active
Where
US
Sanofi phase 2 study testing the approved teplizumab delay regimen in Japanese participants aged 1–34 with stage-2 type 1 diabetes (KIBOU-T1D).
Phase
Status
Recruiting
Where
JP
Advances
Teplizumab (Tzield)
Recruiting Australian Phase 2 placebo-controlled clamp study of six weeks of weekly 2.5 mg tirzepatide in adults with T1D on AID. It is a mechanistic follow-on
Phase
Status
Recruiting
Where
AU
Advances
Tirzepatide as an adjunct in T1D
McGill-led phase 2/3 trial testing whether weekly tirzepatide can help adults using Tandem Control-IQ reduce or eliminate carbohydrate counting and meal announc
Phase
Status
Recruiting
Where
CA · OTHER
Advances
Tandem Control-IQ
PolTREG phase 2 pediatric prevention trial testing expanded regulatory T cells, rituximab, their combination, or control in children with stage 1 type 1 diabete
Phase
Status
Recruiting
Where
EU
Advances
Rituximab (anti-CD20)
NIDDK TrialNet adaptive platform trial comparing teplizumab with low-dose anti-thymocyte globulin in stage-2 T1D to test whether ATG can match or beat the appro
Phase
Status
Not yet recruiting
Where
US
Advances
Teplizumab (Tzield)
Phase 2/3 trial of combination adjunct therapy in type 1 diabetes, included as part of the metabolic-adjunct long tail.
Phase
Status
Active
Where
US
Active phase-2/3 trial testing ustekinumab in adults with recent-onset T1D, following earlier pilot and adolescent signals.
Phase
Status
Active
Where
CA
Advances
Ustekinumab (IL-12/23 p40 blocker)
Zucara phase 2a crossover study of ZT-01, a somatostatin-receptor antagonist intended to restore glucagon release during lows, for nocturnal hypoglycemia in adu
Phase
Status
Recruiting
Where
US · CA
Advances
ZT-01 glucagon-response restorer
The most clinically advanced study of any glucose-sensitive insulin — and it is in type 2 diabetes, not type 1. Lilly is testing LY3938577 against insulin deglu
Phase
Status
Active
Where
US · OTHER
Advances
Glucose-responsive ("smart") insulin
A completed TrialNet Phase 2 trial testing whether 12 months of abatacept (a T-cell costimulation blocker) could delay progression from stage 1 (autoantibody-po
Phase
Status
Completed
Where
US · CA · AU · EU
Advances
Abatacept (CTLA4-Ig)
A phase 2 randomized, placebo-controlled trial testing whether baricitinib — an oral JAK1/JAK2 inhibitor already used for rheumatoid arthritis — can protect the
Phase
Status
Completed
Where
AU
Advances
Teplizumab (Tzield)
First-in-human home-use feasibility test of the dual-hormone iLet bionic pancreas, which adds automated micro-doses of a stable glucagon (dasiglucagon) on top o
Phase
Status
Completed
Where
US
Advances
Beta Bionics iLet Bionic Pancreas
Phase 2 trial of icovamenib (BMF-219), an oral covalent menin inhibitor, in adults with stage-3 T1D who still had some insulin production of their own. Particip
Phase
Status
Terminated
Where
US · CA
Advances
Icovamenib (BMF-219) — oral menin inhibitor
The first randomized controlled trial of a do-it-yourself, open-source closed-loop system (OpenAPS algorithm in AndroidAPS, the "AnyDANA-loop"). In 97 children
Phase
Status
Completed
Where
AU
Advances
OpenAPS (oref0)
A Phase 2b trial that injected the diabetes autoantigen GAD65 (Diamyd) directly into lymph nodes to try to halt the immune attack on insulin-producing cells. It
Phase
Status
Completed
Where
EU
Advances
GAD-alum antigen-specific immunotherapy (Diamyd)
A McGill randomized crossover trial asking whether a fully automated dual-hormone loop — ultra-rapid insulin plus the amylin analog pramlintide, with no carbohy
Phase
Status
Completed
Where
CA
Advances
Insulin + pramlintide (amylin) closed loop
Completed double-blind Phase 2b comparison of hepatocyte-directed-vesicle lispro with ordinary lispro in 227 adults with T1D using insulin degludec, focused on
Phase
Status
Completed
Where
US
Advances
HDV-Insulin Lispro (hepatocyte-directed vesicle)
Multicenter phase-2 trial of the oral tyrosine kinase inhibitor imatinib in adults within 100 days of diagnosis. It met the 12-month C-peptide endpoint, but the
Phase
Status
Completed
Where
US · AU
Advances
Imatinib (tyrosine kinase inhibitor)
A TrialNet Phase 2 trial testing whether a single, brief course of low-dose anti-thymocyte globulin (ATG) — with or without GCSF — can slow the immune destructi
Phase
Status
Completed
Where
US
Advances
Teplizumab (Tzield)
Large Phase 2/3 trial that tested whether the immune drug teplizumab could protect insulin-making cells in people newly diagnosed with type 1 diabetes. It misse
Phase
Status
Completed
Where
US · CA · EU · UK · OTHER
Advances
Teplizumab (Tzield)
Terminated randomized phase-2 study of the anti-CD2 antibody siplizumab in adults with new-onset T1D. The sponsor attributed the early stop to business reasons
Phase
Status
Terminated
Where
UK · EU
Advances
Siplizumab (anti-CD2)
Phase-2 trial targeting CD2-high memory T cells with alefacept. The 12-month primary 2-hour C-peptide endpoint was not significant, but 4-hour C-peptide, insuli
Phase
Status
Terminated
Where
US
Advances
Alefacept (CD2 memory T-cell targeting)
Phase 2 trial of the anti-TNF antibody golimumab in children and young adults with new-onset stage-3 T1D. It preserved C-peptide at 52 weeks and reduced insulin
Phase
Status
Completed
Where
US
Advances
Golimumab (anti-TNF)
Completed Australian phase-2 randomized trial of low-dose weekly tirzepatide versus placebo alongside insulin. It found a large 12-week weight and insulin-dose
Phase
Status
Completed
Where
AU
Advances
Tirzepatide as an adjunct in T1D
A randomized, double-blind, placebo-controlled Phase 2 trial (TrialNet TN-09) testing whether the T-cell co-stimulation modulator abatacept could slow the loss
Phase
Status
Completed
Where
US · CA
Advances
Abatacept (CTLA4-Ig)
A landmark NIH/TrialNet trial showing that a single 14-day course of the anti-CD3 antibody teplizumab delayed the clinical onset of type 1 diabetes by roughly 2
Phase
Status
Completed
Where
US · CA · EU
Advances
Teplizumab (Tzield)
A TrialNet prevention trial testing whether the inexpensive oral immune-modulating drug hydroxychloroquine could slow the earliest stage of type 1 diabetes in p
Phase
Status
Terminated
Where
US · CA · AU · UK · EU
Advances
Hydroxychloroquine for stage-1 T1D prevention
Multicenter double-blind randomized phase-2 trial of ustekinumab in adolescents with recent-onset T1D. It met its 12-month C-peptide endpoint with no increase i
Phase
Status
Completed
Where
UK
Advances
Ustekinumab (IL-12/23 p40 blocker)
A European Phase 2 trial (Ver-A-T1D, NCT04545151) tested whether once-daily slow-release verapamil — a cheap, repurposed blood-pressure pill — could protect the
Phase
Status
Completed
Where
EU · UK
Advances
Verapamil (oral)
Early-phase adjunct-therapy trial targeting cardiometabolic effects of reducing iatrogenic hyperinsulinemia in type 1 diabetes.
Phase
Status
Recruiting
Where
US
Very early (registry "Early Phase 1") single-site study at Zhongshan Hospital, Shanghai, of an off-the-shelf CD7-targeted CAR-T cell product (RD13-02) in 9 adul
Phase
Status
Recruiting
Where
OTHER
Long-running Chicago phase 1/2 donor-islet transplant protocol using intraportal allogeneic islet infusion plus immunosuppression. Included to capture active do
Phase
Status
Active
Where
US
Advances
Donor islet transplant (Lantidra / donislecel)
Recruiting Australian Phase 1, randomised, double-blind, placebo-controlled study of subcutaneous proinsulin peptide/calcitriol liposomes (ASITI-201) in adults
Phase
Status
Recruiting
Where
AU
Advances
ASITI-201 (proinsulin peptide / calcitriol liposomes)
City of Hope pilot study testing whether autologous anti-CD6 chimeric antigen receptor regulatory T cells can be manufactured and safely infused in adults with
Phase
Status
Not yet recruiting
Where
US
Advances
GNTI-122 engineered Tregs (POLARIS)
Nanjing Drum Tower Hospital phase 1 study of ex vivo expanded autologous regulatory T cells in people with T1D, revisiting Treg therapy with a modified preparat
Phase
Status
Recruiting
Where
OTHER
Advances
Autologous polyclonal Treg therapy (T-Rex program)
Early-phase study of a single dose of CARC-101C in autoimmune type 1 diabetes; included as a high-uncertainty engineered-cell immunotherapy signal.
Phase
Status
Not yet recruiting
Where
OTHER
Exploratory early-phase study of allogeneic iPSC-derived pancreatic islet cells given by portal-vein infusion or anterior rectus sheath transplantation in diabe
Phase
Status
Recruiting
Where
OTHER
Advances
Celregen CRG-002 iPSC-derived islets
Recruiting Chinese investigator-initiated first-in-human study of CNK-UT009, a universal CAR-T / NKT cell product, in adults with autoimmune Type 1 diabetes who
Phase
Status
Recruiting
Where
OTHER
First-in-human trial of CNP-103, which its sponsor COUR Pharmaceutical describes as a tolerogenic nanoparticle — a biodegradable particle carrying type 1 diabet
Phase
Status
Recruiting
Where
US
Advances
PIpepTolDC tolerogenic dendritic-cell vaccine
A randomized Phase 1/2a trial testing whether a single intra-arterial infusion of CELZ-201 perinatal tissue-derived cells is safe and potentially beneficial in
Phase
Status
Recruiting
Where
US
Advances
CELZ-201 perinatal tissue-derived cell therapy
Phase 1/2 trial testing whether the RANKL inhibitor denosumab can improve beta-cell function and glycemic control in early T1D.
Phase
Status
Recruiting
Where
US
Advances
Denosumab beta-cell preservation
EndoCell Therapeutics' Phase 1/2a trial of allogeneic human E-islet 01 in adults with long-standing T1D, impaired hypoglycemia awareness, and severe hypoglycemi
Phase
Status
Recruiting
Where
OTHER
Advances
E-islet 01 allogeneic human regenerative islets
First-in-human Phase 1 safety and tolerability study of Encellin's subcutaneous ENCRT thin-film encapsulation device loaded with human primary donor islets. The
Phase
Status
Active
Where
CA
Advances
Encellin thin-film cell encapsulation (ENCRT / ENC-201)
A planned first-in-human Phase 1 study of ENC-103, Encellin's follow-on encapsulation device - a soft, roughly quarter-sized pouch loaded with donor human islet
Phase
Status
Not yet recruiting
Where
CA
Advances
Encellin thin-film cell encapsulation (ENCRT / ENC-201)
Phase 1/2 trial testing whether gastrin can improve donor-islet transplant outcomes in type 1 diabetes.
Phase
Status
Recruiting
Where
US
Advances
Donor islet transplant (Lantidra / donislecel)
Vanderbilt pilot study testing oral semaglutide/Rybelsus metabolic effects in people at early T1D stages receiving clinical teplizumab treatment.
Phase
Status
Recruiting
Where
US
Advances
Teplizumab (Tzield)
Immunocore Phase 1/1b single- and multiple-ascending-dose study of IMC-S118AI, a pre-proinsulin × PD-1 ImmTAAI molecule, in HLA-A*02:01-positive people with Typ
Phase
Status
Not yet recruiting
Where
UK · AU
Advances
IMC-S118AI (PPI × PD-1 ImmTAAI)
Altheia first-in-human trial using a person's own CD34+ hematopoietic stem and progenitor cells, genetically modified ex vivo to express PD-L1, for recent-onset
Phase
Status
Not yet recruiting
Where
EU
Advances
IMMUNOSTEM PD-L1 HSPC gene therapy
A two-person safety study putting donor islets into the front chamber of a blind eye — a site chosen because the graft can be watched through a microscope, and
Phase
Status
Recruiting
Where
US
Advances
Donor islet transplant (Lantidra / donislecel)
City of Hope protocol testing islet transplantation alone in difficult-to-control T1D using a glucocorticoid-free immunosuppressive regimen.
Phase
Status
Active
Where
US
Advances
Donor islet transplant (Lantidra / donislecel)
Trial testing donor-islet transplantation combined with recipient regulatory T cells or deceased-donor vertebral bone marrow therapy to improve immune tolerance
Phase
Status
Recruiting
Where
US
Advances
Donor islet transplant (Lantidra / donislecel)
Recruiting Dutch Phase 1b of autologous tolerogenic dendritic-cell therapy in adults with T1D diagnosed within five years. Target n=10. Safety and immune effect
Phase
Status
Recruiting
Where
EU
Advances
Leiden tolerogenic dendritic-cell therapy
Sequential combination protocol for recent-onset T1D: teplizumab induction, intralymphatic insulin immunotherapy, and low-dose IL-2 maintenance to combine immun
Phase
Status
Not yet recruiting
Where
OTHER
Advances
Teplizumab for new-onset T1D (Tzield)
Novo Nordisk Phase 1 crossover in adults with established T1D, testing weekly NNC0194-0499 (zalfermin, an FGF21 analogue) versus placebo, alone or on top of wee
Phase
Status
Active
Where
EU
First-in-human Otsuka study of OPF-310, encapsulated neonatal porcine islet cells for xenotransplantation, in adults with unstable T1D and repeated severe hypog
Phase
Status
Recruiting
Where
US
Advances
OPF-310 encapsulated porcine islets
City of Hope phase 1 study of an autologous tolerogenic dendritic-cell vaccine loaded with proinsulin peptide in adults with type 1 diabetes, focused on manufac
Phase
Status
Active
Where
US
Advances
PIpepTolDC tolerogenic dendritic-cell vaccine
GentiBio phase 1 study of GNTI-122, a one-time autologous engineered regulatory T-cell therapy made from the participant's own blood cells, in adults recently d
Phase
Status
Recruiting
Where
US
Advances
GNTI-122 engineered Tregs (POLARIS)
Recruiting US Phase 1 single-bolus 12-hour euglycemic clamp of Portal Diabetes’ intraperitoneal U-500 insulin in adults with Type 1 diabetes, compared with intr
Phase
Status
Recruiting
Where
US
Hangzhou Reprogenix's Phase 1 study of RGB-5088 — islets grown from the patient's own chemically reprogrammed (CiPSC) cells — in 10 adults with type 1 diabetes
Phase
Status
Recruiting
Where
OTHER
Advances
CiPSC-derived autologous islets (RGB-5088)
A stem-cell-derived islet therapy gene-edited to hide from the immune system, aiming to cure type 1 diabetes with a single off-the-shelf treatment and no immuno
Phase
Status
Not yet recruiting
Where
US · EU
Advances
Stem-cell-derived islets (zimislecel / VX-880)
Recruiting German Phase 1 euglycemic-clamp crossover of Sam Chun Dang’s oral regular human insulin (SCD0503, S-PASS platform) versus subcutaneous regular human
Phase
Status
Recruiting
Where
EU
First-in-human Seraxis phase 1/2 study of allogeneic pancreatic endocrine cell clusters implanted into the omentum of adults with type 1 diabetes and severe rec
Phase
Status
Not yet recruiting
Advances
Stem-cell-derived islet clusters (Seraxis SR-02)
A prevascularized, pocket-sized scaffold implanted under the skin to house transplanted donor islet cells. In an early Phase 1/2 trial, the first patients achie
Phase
Status
Active
Where
US
Advances
Sernova Cell Pouch Bio-hybrid Organ
UCSD crossover trial testing combined SGLT1/2 inhibition and glucagon-receptor antagonism to address glycemia, ketogenesis, insulin resistance and diabetes burd
Phase
Status
Active
Where
US
University of Chicago investigator-led Phase 1/2 trial testing donor-islet transplantation with tegoprubart (AT-1501), an anti-CD40L monoclonal antibody, as the
Phase
Status
Active
Where
US
Advances
Donor islet transplant (Lantidra / donislecel)
Recruiting Japanese first-in-human Phase 1/2a of TUFF-IPC, insulin-producing cells made from a person's own fat-derived stem cells, transplanted into the mesent
Phase
Status
Recruiting
Where
JP
Advances
TUFF-IPC autologous adipose-derived insulin-producing cells
Phase 1/2 pediatric trial of verapamil for residual insulin preservation after recent-onset T1D.
Phase
Status
Recruiting
Where
EU
Advances
Verapamil (oral)
Most immunotherapy trials test one drug. WAVE T1D tests a sequence: a short induction course of low-dose anti-thymocyte globulin to quiet the immune attack, the
Phase
Status
Recruiting
Where
US
Advances
Low-dose anti-thymocyte globulin (ATG)
Eli Lilly's glucose-sensitive insulin candidate in healthy participants and in people with type 1 diabetes. The design is the most revealing detail: the T1D arm
Phase
Status
Recruiting
Where
EU
Advances
Glucose-responsive ("smart") insulin
Terminated Phase 1/2 anti-CD2 antibody study in recent-onset T1D. Enrollment was held after greater-than-anticipated lymphocyte depletion; the partner then stop
Phase
Status
Terminated
Where
US
Advances
Siplizumab (anti-CD2)
A completed, placebo-controlled Phase 1b study of the CD154-derived peptide OPT101 in 24 adults with T1D. Results posted 10 August 2026 show a small safety data
Phase
Status
Completed
Where
US
Advances
OPT101 (CD40-pathway peptide)
First-in-human trial of stem-cell-derived pancreatic progenitor cells sealed inside an immune-protective implant (PEC-Encap / Encaptra) placed under the skin, a
Phase
Status
Terminated
Where
US · CA
Advances
Stem-cell-derived islets (zimislecel / VX-880)
First-in-human Phase 1 trial of VCTX210 — gene-edited, stem-cell-derived pancreatic cells in an implanted device, designed to make insulin without immunosuppres
Phase
Status
Completed
Where
CA
Advances
Stem-cell-derived islets (zimislecel / VX-880)
A first-in-human trial of CRISPR-edited, stem-cell-derived insulin-making cells engineered to hide from the immune system, so they could be implanted without an
Phase
Status
Terminated
Where
CA
Advances
Stem-cell-derived islets (zimislecel / VX-880)
A Phase 1/2 trial of Vertex's stem-cell-derived islets sealed inside an immune-protective device, aiming to restore insulin production without lifelong immunosu
Phase
Status
Terminated
Where
US · CA · EU · UK · OTHER
Advances
Stem-cell-derived islets (zimislecel / VX-880)
The study that first put Lilly's glucose-sensitive insulin into people, in healthy adults and adults with type 2 diabetes. Completed June 2024 with no posted re
Phase
Status
Completed
Where
US
Advances
Glucose-responsive ("smart") insulin
Novo Nordisk's glucose-sensitive insulin (GSI) candidate, tested in healthy participants and in people with type 1 diabetes. Three parts: single ascending dose,
Phase
Status
Completed
Where
EU
Advances
Glucose-responsive ("smart") insulin
A second, smaller Novo Nordisk Phase 1 of the same glucose-sensitive insulin, run only in people with type 1 diabetes and built around a glucose clamp. The prim
Phase
Status
Completed
Where
EU
Advances
Glucose-responsive ("smart") insulin
Newly registered observational study of Abbott's investigational continuous dual glucose/ketone monitor in 1,200 adults and children with T1D. The study arm des
Phase
Status
Not yet recruiting
Where
AU
Advances
Abbott Libre Duo
Active, not recruiting one-visit autoantibody screen in underserved children and adults in eight Florida counties who have a relative with T1D, another autoimmu
Phase
Status
Active
Where
US
Advances
Islet autoantibody screening (GADA, IA-2A, ZnT8A, IAA)
Study of artificial-intelligence bolus priming layered onto an existing fully automated AIDANET algorithm.
Phase
Status
Not yet recruiting
Where
US
Advances
AIDANET fully closed-loop algorithm
Randomized crossover study in which an algorithm reviews CGM and pump data and proposes personalized setting changes; physicians must approve every recommendati
Phase
Status
Recruiting
Where
OTHER
Trial comparing automated insulin delivery with usual insulin treatment before and during pregnancy in women with type 1 diabetes.
Phase
Status
Recruiting
Where
EU
Study of automated insulin delivery beyond standard glucose metrics, included for broader device-outcome completeness.
Phase
Status
Recruiting
Where
EU
UVA randomized at-home trial of AIDANET, comparing fully closed-loop, hybrid closed-loop, and mixed-mode operation in adults with T1D.
Phase
Status
Recruiting
Where
US
Advances
AIDANET fully closed-loop algorithm
UCSF multicenter randomized trial testing whether automated insulin delivery can replace intravenous insulin protocols for intrapartum glucose management in pre
Phase
Status
Recruiting
Where
US
Advances
Tandem Control-IQ+
Sanofi's recruiting observational cohort following people who received teplizumab for stage 2 T1D as part of ordinary care, for up to 10 years. It measures time
Phase
Status
Recruiting
Where
US · OTHER
Advances
Teplizumab (Tzield)
Active protocol for allogeneic regenerative islet transplantation in brittle type 1 diabetes, adding another cell-replacement entry to the transplant long tail.
Phase
Status
Recruiting
Where
OTHER
Advances
Donor islet transplant (Lantidra / donislecel)
Adoption study for the Argus 2.0 glucose monitoring system.
Phase
Status
Not yet recruiting
Where
US
A free, general-population program at Colorado's Barbara Davis Center that blood-tests children for the autoantibodies of early type 1 diabetes (and celiac dise
Phase
Status
Recruiting
Where
US
Advances
Islet autoantibody screening (GADA, IA-2A, ZnT8A, IAA)
First registered study of Indigo's HALO implantable sensor, evaluating glucose, ketone and lactate accuracy and stability against venous reference measurements,
Phase
Status
Not yet recruiting
Advances
Indigo HALO continuous multi-metabolite monitor
Recruiting UK study comparing finger-prick glucose with venous OGTT and testing whether a capillary OGTT can be performed acceptably at home. Its T1D cohorts in
Phase
Status
Recruiting
Where
UK
Advances
Oral glucose tolerance test (OGTT) for T1D staging
Study evaluating the accuracy and precision of the CareSens Air 3 continuous glucose monitoring system in adults with T1D.
Phase
Status
Recruiting
Where
US
Pregnancy study comparing commercial and open-source closed-loop use in T1D, relevant to real-world AID safety and access in pregnancy.
Phase
Status
Recruiting
Where
US
Advances
AndroidAPS
University of Waterloo / Stanford pilot testing an investigational combined glucose-ketone sensor during temporary insulin pump suspension in adults with type 1
Phase
Status
Not yet recruiting
Where
US
Advances
Concept: closed loops that act on ketones
Study of DBLG1 closed-loop insulin delivery effects on glycemic control and patient-reported outcomes in adults with T1D.
Phase
Status
Recruiting
Where
EU
Advances
Diabeloop DBLG1
Recruiting Sanofi-sponsored study screening up to 3,500 children and adolescents who have a first-degree relative with T1D at sites in Saudi Arabia and the UAE,
Phase
Status
Recruiting
Where
OTHER
Advances
Islet autoantibody screening (GADA, IA-2A, ZnT8A, IAA)
Pilot trial of early automated insulin delivery soon after T1D diagnosis.
Phase
Status
Not yet recruiting
Where
US
Study of early automated insulin delivery therapy on diabetes control, comorbidities and cost-effectiveness.
Phase
Status
Not yet recruiting
Where
EU
A UK general-population study testing whether it is feasible and acceptable to screen children aged 3-13 for the early immune "fingerprints" of type 1 diabetes
Phase
Status
Recruiting
Where
UK
Advances
Teplizumab (Tzield)
A completed-enrolment observational study of Medtronic's InPen connected insulin pen in adolescents and young adults with T1D. No results posted; primary comple
Phase
Status
Active
Where
US
Advances
MiniMed Go / InPen smart MDI system
Senseonics multicenter study evaluating the performance and safety of the Eversense Gemini system with flash glucose measurement enhancements against reference
Phase
Status
Recruiting
Where
US
Advances
Senseonics Eversense 365
Post-approval study of non-adjunctive Eversense CGM use, relevant to long-wear implantable CGM maturity.
Phase
Status
Active
Where
US
Advances
Senseonics Eversense 365
Feasibility study of extended-wear insulin infusion set options during home use in T1D.
Phase
Status
Active
Where
US
University of Colorado/UVA feasibility testing of AIDANET fully closed-loop operation at home in adolescents and adults, including groups with higher baseline H
Phase
Status
Active
Where
US
Advances
AIDANET fully closed-loop algorithm
A landmark public-health program that screens young children across Bavaria for the islet autoantibodies that mark early-stage type 1 diabetes, before any sympt
Phase
Status
Recruiting
Where
EU
Advances
Islet autoantibody screening (GADA, IA-2A, ZnT8A, IAA)
MiniMed pivotal safety study of the system now publicly launched as MiniMed Flex and still registered under the NMX8-AID name, paired with the DS5 / Simplera Sy
Phase
Status
Recruiting
Where
US · AU
Advances
MiniMed Flex (formerly NMX8-AID)
Yale observational study validating a self-administered fingerstick glucose tolerance test against in-clinic venous OGTT measurements in people at risk for clin
Phase
Status
Recruiting
Where
US
Advances
Oral glucose tolerance test (OGTT) for T1D staging
Adult hybrid-closed-loop effectiveness trial in type 1 diabetes.
Phase
Status
Recruiting
Where
US
Beta Bionics prospective real-world cohort collecting one-year safety and effectiveness data for the iLet Dosing Decision Software in people aged 6 and older wi
Phase
Status
Recruiting
Where
US
Advances
Beta Bionics iLet Bionic Pancreas
Randomized crossover study asking whether inhaled Technosphere insulin for a meal is safer than a pump-delivered rapid-acting analogue when adults using Control
Phase
Status
Recruiting
Where
US
Advances
Inhaled insulin (Afrezza)
Recruiting European observational screening protocol testing islet autoantibodies in children and adults aged 1–45 who have a relative or close friend diagnosed
Phase
Status
Recruiting
Where
EU
Advances
Islet autoantibody screening (GADA, IA-2A, ZnT8A, IAA)
OHSU study of a fully closed-loop iPancreas algorithm that detects hyperglycemia patterns and delivers correction insulin, testing context-aware dosing against
Phase
Status
Recruiting
Where
US
Advances
Insulin + pramlintide (amylin) closed loop
A 30-person, single-arm, open-label study of infused iPSC-derived islet cells, run by Peking University First Hospital with Hangzhou Reprogenix — the company be
Phase
Status
Not yet recruiting
Where
OTHER
Advances
CiPSC-derived autologous islets (RGB-5088)
University of Chicago recruiting protocol for allogeneic human islet transplantation in brittle T1D.
Phase
Status
Recruiting
Where
US
Advances
Donor islet transplant (Lantidra / donislecel)
PRECISION II accuracy study of the LabPatch glucose sensing system.
Phase
Status
Active
Where
US
Safety/effectiveness study of the Luna automated insulin-delivery system in people with T1D.
Phase
Status
Active
Where
US
Clinical evaluation of Medtronic implantable insulin pump technology in adults with T1D, a rare long-horizon delivery-device pathway.
Phase
Status
Recruiting
Where
EU
Study of MiniMed 780G performance in people with T1D complicated by gastroparesis, a difficult meal-absorption context for AID.
Phase
Status
Recruiting
Where
US
Advances
Medtronic MiniMed 780G (pump)
Recruiting New Zealand study evaluating investigational Omnipod M and Omnipod S automated-insulin-delivery systems in people aged 2-70 with T1D.
Phase
Status
Recruiting
Where
AU
Recruiting European/Israeli study comparing Medtronic's experimental NMX8 AID system with the MiniMed 780G over 12 weeks in people aged 2 and older with insulin
Phase
Status
Recruiting
Where
EU · OTHER
Advances
MiniMed Flex (formerly NMX8-AID)
A not-yet-recruiting randomized crossover study comparing open-source AID (Loop, AndroidAPS or OpenAPS) with commercial AID (Control-IQ or Omnipod 5) during sta
Phase
Status
Not yet recruiting
Where
US · CA
Advances
Fully closed-loop, insulin-only (no meal announcement)
Registry/observational study of open-source artificial-pancreas system use among people with T1D in China.
Phase
Status
Recruiting
Where
OTHER
Advances
AndroidAPS
Recruiting Belgian study using repeated Dexcom CGM, oral glucose-tolerance tests, and (in older participants) hyperglycemic clamps to see whether glucose-variab
Phase
Status
Recruiting
Where
EU
Advances
Islet autoantibody screening (GADA, IA-2A, ZnT8A, IAA)
Extension study following recent-onset T1D participants treated in teplizumab PROTECT to track longer-term safety and disease-course signals.
Phase
Status
Active
Where
US · EU · CA · UK
Advances
Teplizumab for new-onset T1D (Tzield)
Automated-insulin-delivery trial comparing qualitative meal-size estimation against formal carbohydrate counting.
Phase
Status
Recruiting
Where
OTHER
Quebec feasibility study of islet-autoantibody screening for first-degree relatives of people with type 1 diabetes, comparing centralized and decentralized foll
Phase
Status
Not yet recruiting
Where
CA
Advances
Islet autoantibody screening (GADA, IA-2A, ZnT8A, IAA)
Novo Nordisk observational study following adults with type 1 diabetes newly prescribed once-weekly insulin icodec in usual clinical practice in Germany and Ita
Phase
Status
Active
Where
EU
Advances
Once-weekly insulin icodec (Awiqli)
Czech real-world study evaluating efficacy and safety of the Medtrum TouchCare Nano A8 patch pump with APGO automated insulin-delivery algorithm.
Phase
Status
Recruiting
Where
EU
Advances
Medtrum TouchCare Nano
Study of the ROME GS glucose sensing system in people with diabetes, included as CGM pipeline surveillance.
Phase
Status
Recruiting
Where
US
Long-term Sanofi registry following people with stage 2 type 1 diabetes, including those treated with Tzield (teplizumab-mzwv) as standard care, to collect safe
Phase
Status
Recruiting
Where
US
Advances
Teplizumab (Tzield)
Niche pediatric/adolescent protocol combining umbilical cord blood stem cells and islet cells in monogenic immunodeficiency-associated T1D.
Phase
Status
Recruiting
Where
OTHER
Newly registered 15-day study comparing the GS3 real-time CGM with venous plasma reference measurements across glucose ranges in 36 adults with T1D.
Phase
Status
Recruiting
Where
OTHER
Advances
SiBionics GS3
Trial comparing simplified meal boluses with carbohydrate counting in adolescents using hybrid closed-loop systems.
Phase
Status
Recruiting
Where
US
Prospective Italian network designed to follow children and adults found with at least one islet autoantibody for up to ten years, tracking progression to stage
Phase
Status
Not yet recruiting
Where
EU
Advances
D1Ce Screen / Italy national screening (Law 130/2023)
Insulet randomized crossover trial comparing investigational Omnipod 6 with Omnipod 5 in people with type 1 or type 2 diabetes and suboptimal glycemia. It is th
Phase
Status
Recruiting
Where
US
Advances
Omnipod 6 (AID)
Recruiting Sanofi chart-review study of people who already received teplizumab for stage 2 T1D through managed-access programmes. It describes who was treated a
Phase
Status
Recruiting
Where
UK · EU
Advances
Teplizumab (Tzield)
Trial comparing three-day and seven-day insulin infusion sets in people with T1D.
Phase
Status
Recruiting
Where
EU
The backbone US/international screening and natural-history study that tests blood from relatives of people with T1D for islet autoantibodies, then monitors tho
Phase
Status
Recruiting
Where
US · UK · EU · CA · AU
Advances
Teplizumab (Tzield)
Northwestern observational implementation study integrating islet-autoantibody screening into routine pediatric well-child visits. Clinics receive education, or
Phase
Status
Not yet recruiting
Where
US
Advances
Islet autoantibody screening (GADA, IA-2A, ZnT8A, IAA)
The study behind the most-cited result in the immune-evasion field: gene-edited donor islets that survived in a person with type 1 diabetes for 12 months, and w
Phase
Status
Recruiting
Where
EU
Advances
Sana Biotechnology SC451 (hypoimmune stem-cell islets)
A randomized non-inferiority trial in adults with type 1 diabetes testing an open-source automated insulin delivery system run with no meal announcement at all
Phase
Status
Completed
Where
AU · OTHER
Advances
OpenAPS (oref0)
Completed 12-week randomized comparison in which both groups used the DIA:CONN P8: the intervention group used its app-supported carbohydrate/meal bolus calcula
Phase
Status
Completed
Where
OTHER
Advances
DIA:CONN P8 smart insulin pen
An open-label pilot study in 12 people with recent-onset type 1 diabetes that tested injecting the GAD65 autoantigen vaccine (Diamyd / GAD-alum) directly into a
Phase
Status
Completed
Where
EU
Advances
GAD-alum antigen-specific immunotherapy (Diamyd)
The first head-to-head crossover trial of two automated insulin delivery systems in the hardest-to-control age group (14-29). The advanced hybrid closed-loop sy
Phase
Status
Completed
Where
US · EU · OTHER
Advances
Medtronic MiniMed 780G (SmartGuard)
A 243-person, 12-month randomized Dutch trial (DARE, NCT05669547) testing the Inreda AP — a fully automated, dual-hormone (insulin + glucagon) artificial pancre
Phase
Status
Completed
Where
EU
Advances
Tandem Control-IQ
Pivotal in-home study supporting the first FDA-approved commercial hybrid closed-loop system for type 1 diabetes.
Phase
Status
Completed
Where
US
Advances
Medtronic MiniMed 670G (first hybrid closed loop)
Completed Medtronic observational wear study of MiniMed Fit payload adhesive components in different body locations over seven days, supporting development of t
Phase
Status
Completed
Where
US
Advances
MiniMed Fit (patch pump)
Pediatric observational wear study of non-functional MiniMed Fit payloads, testing seven-day adhesive survival and placement before the future patch pump reache
Phase
Status
Completed
Where
US
Advances
MiniMed Fit (patch pump)
Oregon Health & Science University ran the same model-predictive-control closed loop two ways — insulin only, and insulin plus the amylin analogue pramlintide —
Phase
Status
Completed
Where
US
Advances
Insulin + pramlintide (amylin) closed loop
The pivotal single-arm trial of the Omnipod 5 tubeless, on-body hybrid closed-loop system in children and adults with type 1 diabetes. It showed improved HbA1c
Phase
Status
Completed
Where
US
Advances
Omnipod 5 (pump)
Single-arm multicenter trial that tested the tubeless Omnipod 5 automated insulin delivery system in 80 very young children (ages 2.0-5.9) with type 1 diabetes.
Phase
Status
Completed
Where
US
Advances
Omnipod 5 (pump)
Insulet's pivotal crossover trial of SmartAdjust 2.0 — the algorithm behind the next Omnipod. 132 existing Omnipod 5 users, aged 2 to 70, spent four weeks on ea
Phase
Status
Completed
Where
US
Advances
Omnipod 5 (SmartAdjust AID)
Completed six-person, ten-hour feasibility study of the University of Bern's smartphone-based hybrid closed-loop algorithm and its CGM, pump, user-interface and
Phase
Status
Completed
Where
OTHER
Each trial links back to the therapy it advances and out to its ClinicalTrials.gov record. Science journalism, not medical advice.